US20220146537A1 - Method for analyzing blood coagulation characteristics of blood specimen - Google Patents

Method for analyzing blood coagulation characteristics of blood specimen Download PDF

Info

Publication number
US20220146537A1
US20220146537A1 US17/427,000 US202017427000A US2022146537A1 US 20220146537 A1 US20220146537 A1 US 20220146537A1 US 202017427000 A US202017427000 A US 202017427000A US 2022146537 A1 US2022146537 A1 US 2022146537A1
Authority
US
United States
Prior art keywords
time
coagulation
specimen
fviii
weighted average
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/427,000
Other languages
English (en)
Inventor
Toshiki Kawabe
Yukio Oda
Midori Shima
Keiji Nogami
Kenichi Ogiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public University Corp Nara Medical University
Sekisui Medical Co Ltd
Original Assignee
Public University Corp Nara Medical University
Sekisui Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Public University Corp Nara Medical University, Sekisui Medical Co Ltd filed Critical Public University Corp Nara Medical University
Assigned to PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY reassignment PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHIMA, MIDORI, NOGAMI, KEIJI, OGIWARA, Kenichi
Assigned to SEKISUI MEDICAL CO., LTD. reassignment SEKISUI MEDICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAWABE, TOSHIKI, ODA, YUKIO
Assigned to PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY reassignment PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD ASSIGNOR'S EXECUTION DATE PREVIOUSLY RECORDED ON REEL 057026 FRAME 0158. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: SHIMA, MIDORI, OGIWARA, Kenichi, NOGAMI, KEIJI
Publication of US20220146537A1 publication Critical patent/US20220146537A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4905—Determining clotting time of blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Definitions

  • the present invention relates to a method for analyzing blood coagulation characteristics of a blood specimen. Further, the present invention relates to a program and an apparatus, for analyzing blood coagulation characteristics of a blood specimen.
  • a blood coagulation test is a test for examining a hemostatic ability or a fibrinolytic capacity, of a patient.
  • coagulation reaction that occurs after a reagent is added to a blood specimen of a patient is optically measured.
  • a time that is required to reach a predetermined state of coagulation is measured as the blood coagulation time.
  • Typical examples of the blood coagulation time include prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time.
  • PT prothrombin time
  • APTT activated partial thromboplastin time
  • thrombin time The prolongation of the blood coagulation time reflects a bleeding tendency in vivo.
  • the causes of the prolongation for example, 1) abnormal amount of blood coagulation factors, 2) presence of antibodies against, for example, blood components constituting the blood coagulation system, and a reagent for measuring the blood coagulation time, and 3) administration of a drug that inhibits the blood coagulation reaction are conceivable.
  • a coagulation reaction curve can be obtained by measuring the amount of blood coagulation reaction over time after addition of a reagent to a blood specimen.
  • the coagulation reaction curve has a different shape depending on the type of the abnormality in the blood coagulation system (Non Patent Literature 1). For this reason, a method for determining the abnormality in the blood coagulation system on the basis of a coagulation reaction curve has been disclosed.
  • Patent Literatures 1, 2, and 3 disclose a method for evaluating the presence or absence of abnormalities of coagulation factors in a patient, on the basis of the parameters related to primary and secondary differential curves of a coagulation reaction curve for the blood of the patient, for example, the maximum coagulation rate, the maximum coagulation acceleration, and the maximum coagulation deceleration.
  • Hemophilia is a disease in which a coagulation factor VIII (FVIII) or a coagulation factor IX (FIX) is congenitally deficient, or functionally abnormal. Assuming that the activity of a healthy individual is 100%, an individual having a FVIII activity of less than 40% is classified as hemophilia A, and an individual having a FIX activity of less than 40% is classified as hemophilia B. Further, the severity of hemophilia is classified in accordance with the activity level.
  • Patent Literature 4 discloses a method for determining the severity of hemophilia on the basis of the average rate of the change in the coagulation rate during the time when the coagulation reaction of a patient reaches the maximum coagulation rate or the maximum coagulation acceleration.
  • a primary differential curve of an actual coagulation reaction curve of a blood specimen may not be unimodality due to the influence of the components contained in the specimen or the reagent used in the test, or due to the difference in the measurement method.
  • the waveform analysis is conducted by performing a smoothing treatment to make the primary differential curve unimodal.
  • the smoothing treatment for making the primary differential curve unimodal it is assumed that the obtained curve does not reflect the clinical status of a patient in detail because of the loss of the waveform information due to the smoothing treatment. For this reason, an analysis method that can accurately evaluate the blood coagulation characteristics of a specimen even from a primary differential curve that is not unimodal regardless of the smoothing treatment has been demanded.
  • the present inventors found parameters having a relationship with the activities of coagulation factor VIII (FVIII) and coagulation factor IX (FIX), derived from a coagulation reaction curve of a blood.
  • the present inventors also found a method for analyzing the activity level of FVIII or FIX in a blood specimen and the presence or absence of activity abnormality of FVIII or FIX in a blood specimen, on the basis of the parameters.
  • the present invention provides the following.
  • a method for analyzing a blood specimen comprising:
  • the plurality of parameters comprise a plurality of parameters characterizing a plurality of calculation target areas, respectively of the waveform related to a coagulation rate, a plurality of parameters characterizing a plurality of calculation target areas, respectively of the waveform related to a coagulation acceleration, or a combination of both pluralities of parameters.
  • the plurality of parameters comprise one or more selected from the group consisting of:
  • a weighted average time vT for the weighted average height
  • a W flattening vAW for the weighted average height
  • a B time rate vTB for the weighted average time
  • a W time rate vTW for the weighted average time
  • an average time vTa an average height vHa
  • a B flattening vABa for the average height
  • a W flattening vAWa for the average height, an area start point time vTs, an area end point time vTe, an area median time vTm, an area time width vTr, a main peak start point time vNs, a main peak end point time vNe, and a main peak width vN for the plurality of calculation target areas of the waveform related to a coagulation rate;
  • a weighted average time pT a weighted average height pH, a peak width pB, and a weighted average peak width pW
  • a B flattening pAB for the weighted average height
  • a W flattening pAW for the weighted average height
  • a B time rate pTB for the weighted average time
  • a W time rate pTW for the weighted average time
  • main peak start point time pNs a main peak end point time pNe
  • a main peak width pN for a plurality of calculation target areas of a plus peak of the waveform related to a coagulation acceleration
  • a weighted average time mT a weighted average height mH, a peak width mB, and a weighted average peak width mW
  • a B flattening mAB for the weighted average height
  • a W flattening mAW for the weighted average height
  • a B time rate mTB for the weighted average time
  • a W time rate mTW for the weighted average time
  • main peak start point time mNs a main peak end point time mNe
  • a main peak width mN for a plurality of calculation target areas of a minus peak of the waveform related to a coagulation acceleration.
  • the waveform related to a coagulation rate is defined as F(t) (t represents time) and each of t1 and t2 is defined as a time when F(t) is a predetermined value x (t1 ⁇ t2)
  • the calculation target area is an area satisfying F(t) ⁇ x
  • the vT and vH are represented by the following formulas, respectively:
  • vTa, vHa, and vTm are represented by the following formulas, respectively, when F(t), t1, and t2 are defined as described above and the number of data points from F(t1) to F(t2) is n:
  • vTm t ⁇ ⁇ 1 + t ⁇ ⁇ 2 2 ( 7 )
  • the vB represents a time length to be F(t) ⁇ x from t1 to t2,
  • the vW represents a time length to be F(t) ⁇ vH from t1 to t2,
  • the vTr represents a time length from vTs to vTe
  • the vN represents a time length from vNs to vNe
  • the vAB represents a ratio of the vH to the vB
  • the vAW represents a ratio of the vH to the vW
  • the vTB represents a ratio of the vT to the vB
  • the vTW represents a ratio of the vT to the vW
  • the vABa represents a ratio of the vHa to the vB
  • the vAWa represents a ratio of the vHa to the vW.
  • the waveform related to a coagulation acceleration is defined as F′(t) (t represents time) and a time when F′(t) is a predetermined value x is defined as t1, t2 (t1 ⁇ t2)
  • the calculation target area is an area satisfying F′(t) ⁇ x
  • the pT and pH are represented by the following formulas, respectively:
  • the pB represents a time length to be F′(t) ⁇ x from t1 to t2,
  • the pW represents a time length to be F′(t) ⁇ pH from t1 to t2,
  • the pN represents a time length from pNs to pNe
  • the pAB represents a ratio of the pH to the pB
  • the pAW represents a ratio of the pH to the pW
  • the pTB represents a ratio of the pT to the pB
  • the pTW represents a ratio of the pT to the pW.
  • the waveform related to a coagulation acceleration is defined as F′(t) (t represents time) and a time when F′(t) is a predetermined value x is defined as t1, t2 (t1 ⁇ t2)
  • the calculation target area is an area satisfying F′(t) ⁇ x
  • the mT and mH are represented by the following formulas, respectively:
  • the mB represents a time length to be F′(t) ⁇ x from t1 to t2,
  • the mW represents a time length to be F′(t) ⁇ mH from t1 to t2,
  • the mN represents a time length from mNs to mNe
  • the mAB represents a ratio of the mH to the mB
  • the mAW represents a ratio of the mH to the mW
  • the mTB represents a ratio of the mT to the mB
  • the mTW represents a ratio of the mT to the mW.
  • the determination comprises comparing a group of the plurality of parameters with a corresponding group of parameters for a plurality of template blood specimens, and determining an activity level or activity abnormality of a coagulation factor in the subject blood specimen on the basis of a result of the comparison, wherein
  • each of the template blood specimens is a blood specimen of which an activity level or presence or absence of activity abnormality of the coagulation factor is known.
  • a second determination step of determining an activity level or activity abnormality of a blood coagulation factor IX in a subject blood specimen with which a blood coagulation factor VIII is determined to be not abnormal wherein
  • the second determination step comprises comparing a group of parameters for the subject blood specimen with a corresponding group of parameters for a plurality of template blood specimens each of which an activity level or presence or absence of activity abnormality of a blood coagulation factor IX is known, and determining an activity level or activity abnormality of the blood coagulation factor IX in the subject blood specimen on the basis of a result of the comparison.
  • the activity level or the presence or absence of the activity abnormality (for example, deficiency), of FVIII or FIX in a blood specimen can be analyzed.
  • the present invention is useful for the determination of hemophilia A or hemophilia B, or the determination of the severity of a patient with hemophilia.
  • FIG. 1 illustrates one embodiment of a procedure for the method for analyzing a blood specimen according to the present invention.
  • FIG. 2 illustrates one embodiment of a procedure for the step of data analysis shown in FIG. 1 .
  • FIG. 3 shows one example of a coagulation reaction curve.
  • FIG. 4 shows one example of a coagulation reaction curve after pretreatment.
  • FIG. 5A shows a partially enlarged diagram of one example of a coagulation reaction curve.
  • FIG. 5B shows a partially enlarged diagram of one example of a coagulation reaction curve after pretreatment.
  • FIG. 6 shows one example of a corrected zero-order curve.
  • FIG. 7 shows one example of a corrected primary curve.
  • FIG. 8 shows a conceptual diagram of parameters calculated from a waveform related to a coagulation rate.
  • FIG. 9 shows a conceptual diagram for illustrating a calculation target area level, ranges of the corrected zero-order and corrected primary curves to be analyzed, and a weighted average point.
  • FIG. 10 shows a conceptual diagram of parameters calculated from a secondary curve.
  • FIG. 11 shows a conceptual diagram for indicating vTs, vTe, vTr, vNs, vNe, and vN.
  • FIG. 12 shows conceptual diagrams for indicating a weighted average point, vTs, vTe, vB, and vW.
  • the dotted line indicates a 10% calculation target area of a primary curve.
  • FIG. 13 shows a conceptual diagram for indicating vTa, vHa, and vTm.
  • FIG. 14A shows a conceptual diagram for illustrating, for example, a weighted average point in a case where the calculation target area level is 10%.
  • FIG. 14B shows a conceptual diagram for illustrating, for example, a weighted average point in a case where the calculation target area level is 806.
  • FIG. 15 shows a conceptual diagram for illustrating a configuration of an automatic analyzer for conducting the method for analyzing a blood specimen according to the present invention.
  • FIG. 16 shows regression lines for a parameter group A-1.
  • the test specimen (Sample AF) is derived from a patient with severe hemophilia A having a FVIII activity of less than 0.2°.
  • the FVIII activity and APTT of template and test specimens are shown on the horizontal axis and the vertical axis, respectively.
  • FIG. 17A shows a regression line with a specimen (Template A) having the highest correlation coefficient in FIG. 16 .
  • FIG. 17B shows corrected primary curves of the test specimen (Sample AF) and Template A.
  • FIG. 18 shows distributions of the FVIII activity and APTT for the test specimens and template specimens used in Example 5.
  • A FVIII activity
  • B APTT.
  • Left test specimens
  • Right template specimens.
  • FIG. 19 shows influence of the allowable tilt range and correlation coefficient threshold in regression analysis on the FVIII-deficient concordance rate and FVIII activity-level concordance rate based on determination criteria 1.
  • FIG. 20 shows influence of the allowable tilt range and correlation coefficient threshold in regression analysis on the FVIII-deficient concordance rate and FVIII activity-level concordance rate based on determination criteria 2.
  • FIG. 21 shows influence of the allowable tilt range and correlation coefficient threshold in regression analysis on the FVIII-deficient concordance rate and FVIII activity-level concordance rate based on determination criteria 3
  • the present invention relates to an analysis of the characteristics related to blood coagulation of a blood specimen.
  • a blood specimen may be referred to as a specimen.
  • the present invention relates to an analysis of the activity level or the presence or absence of the activity abnormality, of a blood coagulation time prolongation factor component in a specimen with a prolonged blood coagulation time.
  • the present invention relates to an analysis of the activity level or the presence or absence of the activity abnormality, of a coagulation factor VIII (hereinafter, also referred to as FVIII) or a coagulation factor IX (hereinafter, also referred to as FIX).
  • FVIII coagulation factor VIII
  • FIX coagulation factor IX
  • one embodiment of the present invention is a method for analyzing a blood specimen, and more specifically, a method for determining the activity level or the presence or absence of the activity abnormality, of a blood coagulation time prolongation factor component, suitably FVIII and/or FIX in a blood specimen.
  • a blood coagulation time prolongation factor component suitably FVIII and/or FIX in a blood specimen.
  • the method for analyzing a blood specimen according to the present invention includes: acquiring a waveform related to a coagulation rate or a coagulation acceleration, of a sample obtained by mixing a test specimen with a reagent for measuring coagulation time; extracting multiple parameters characterizing the waveform related to the coagulation rate or the coagulation acceleration; and determining an activity level or activity abnormality, of a blood coagulation time prolongation factor component in the test specimen on the basis of the multiple parameters.
  • a waveform related to a coagulation rate or a coagulation acceleration of a sample obtained by mixing a test specimen with a reagent for measuring coagulation time
  • extracting multiple parameters characterizing the waveform related to the coagulation rate or the coagulation acceleration includes: determining an activity level or activity abnormality, of a blood coagulation time prolongation factor component in the test specimen on the basis of the multiple parameters.
  • a sample is prepared from a test specimen (step 1 ), and then coagulation reaction measurement for the sample is performed (step 2 ).
  • a waveform related to the coagulation rate or the coagulation acceleration is acquired for the sample, and then a predetermined analysis is performed on the waveform (step 3 ).
  • determination determination of an activity level or activity abnormality, of a blood coagulation time prolongation factor component of the test specimen is performed (step 4 ).
  • a sample from a test specimen in step 1 Preparation of a sample from a test specimen in step 1 , and coagulation reaction measurement of the sample in step 2 will be described.
  • the coagulation reaction measurement will be described with reference to a measurement of an activated partial thromboplastin time (APTT), and changes to other coagulation reaction measurements (for example, prothrombin time (PT) measurement) can be performed by a person skilled in the art.
  • APTT activated partial thromboplastin time
  • PT prothrombin time
  • a specimen derived from a subject who is required to be inspected for the blood coagulation ability is included, for example, a specimen with abnormal blood coagulation, or a specimen suspected of abnormal blood coagulation is included, and more specifically, a specimen with a prolonged blood coagulation time, or a specimen suspected of a prolonged blood coagulation time is included.
  • a specimen with abnormal blood coagulation or a specimen suspected of abnormal blood coagulation is included, and more specifically, a specimen with a prolonged blood coagulation time, or a specimen suspected of a prolonged blood coagulation time is included.
  • blood plasma of a subject is used.
  • a well-known anticoagulant agent that is usually used in a coagulation test can be added. For example, blood is collected with the use of a blood collection tube in which sodium citrate is put, and then centrifuged, as a result of which blood plasma is obtained.
  • the obtained test specimen is mixed with a reagent for measuring coagulation time, and a sample for coagulation reaction measurement is prepared.
  • a reagent for measuring coagulation time a reagent for APTT measurement may be used, and for example, a contact factor-based activator, or a phospholipid can be included.
  • the activator include ellagic acid, cerite, kaolin, silica, and a polyphenol compound.
  • the phospholipid include phospholipids derived from an animal, a plant, and synthesis. Examples of the phospholipid derived from an animal include phospholipids derived from a rabbit brain, a chicken, and a pig.
  • Examples of the phospholipid derived from a plant include phospholipids derived from soybeans. Further, a buffer solution such as Tris hydrochloric acid may be added to the sample, as needed. Alternatively, as the reagent for the APTT measurement, a commercially available reagent for measuring APTT may be used. As an example of the commercially available reagent for measuring APTT, Coagpia APTT-N (manufactured by Sekisui Medical Co., Ltd.) is included. The prepared sample is heated, and a contact factor in the sample is activated. The temperature during the heating is, for example, 30° C. or more and 40° C. or less, and preferably 35° C. or more and 39° C. or less.
  • a calcium chloride solution for example, a calcium chloride solution, Coagpia APTT-N manufactured by Sekisui Medical Co., Ltd.
  • the coagulation reaction of the mixture after addition of the calcium chloride solution can be measured.
  • a common means for example, an optical means for measuring an amount of scattered light, transmittance, absorbance, or the like, a mechanical means for measuring a viscosity of blood plasma, or the like may be used.
  • the time to be measured can be several tens of seconds to around 5 minutes from the time point of the addition of the calcium chloride solution.
  • the measurement can be repeated at predetermined intervals.
  • the measurement may be performed, for example, at 0.1-second intervals.
  • the temperature of the reaction mixture during the measurement is, for example, 30° C. or more and 40° C. or less, and preferably 35° C. or more and 39° C. or less.
  • the reaction start time of the coagulation reaction can be typically defined as the time point when the calcium chloride solution is added to a sample containing a test specimen, however, other timings may be defined as the reaction start time. Further, various kinds of conditions for measurement can be appropriately set depending on, for example, the test specimen, the reagent, or the measuring means.
  • a series of operations in the above-described coagulation reaction measurement may be performed by using an automatic analyzer.
  • an automatic analyzer a blood coagulation automatic analyzer, CP3000 (manufactured by Sekisui Medical Co., Ltd.) can be included.
  • some of the operations may be performed manually.
  • the preparation of the test specimen is performed by a person, and the subsequent operations can be performed by an automatic analyzer.
  • the data analysis in step 3 will be described.
  • the flow of the data analysis is shown in FIG. 2 .
  • the data analysis in step 3 may be performed in parallel with the coagulation reaction measurement in step 2 , or may be performed later by using the data of the coagulation reaction measurement performed in advance.
  • step 3 a the measurement data in the coagulation reaction measurement is acquired.
  • the data are data that reflect, for example, the coagulation reaction process of a sample, obtained by the APTT measurement in step 2 described above.
  • data indicating the time change of the degree of progress of the coagulation reaction for example, amount of scattered light
  • the data obtained by the coagulation reaction measurement are also referred to as coagulation reaction information in the present specification.
  • FIG. 3 is a coagulation reaction curve based on the amount of scattered light, and the horizontal axis indicates the elapsed time (coagulation reaction time) after addition of a calcium chloride solution, and the vertical axis indicates the amount of scattered light.
  • the coagulation reaction of the mixture proceeds with the lapse of time, so that the amount of scattered light is increased.
  • a curve showing the change in the coagulation reaction amount with respect to the coagulation reaction time indicated by, for example, such an amount of scattered light is referred to as a coagulation reaction curve.
  • the coagulation reaction curve based on the amount of scattered light is usually sigmoid.
  • the coagulation reaction curve based on the amount of transmitted light is usually reverse sigmoid.
  • data analysis using the coagulation reaction curve based on the amount of scattered light will be described as the coagulation reaction information. It is obvious to a person skilled in the art that similar treatment can be performed also in a case of the data analysis using a coagulation reaction curve based on the amount of transmitted light or the absorbance as the coagulation reaction information.
  • the coagulation reaction curve obtained by a mechanical means such as a viscosity change of a mixture may be subjected to the analysis.
  • a pretreatment of the coagulation reaction curve is performed.
  • the pretreatment includes a smoothing treatment for removing noise, and a zero point adjustment.
  • FIG. 4 shows one example of the coagulation reaction curve of FIG. 3 , for which the pretreatment (smoothing treatment and zero point adjustment) has been performed. Any known noise removal method can be used for the smoothing treatment.
  • FIGS. 5A and 5B show partially enlarged diagrams of the coagulation reaction curve of FIG. 3 before and after the pretreatment, respectively. In FIG. 5B , the smoothing treatment and the zero point adjustment are performed on the data of FIG. 5A .
  • the height of the coagulation reaction curve depends on the fibrinogen concentration of a test specimen. On the other hand, since the fibrinogen concentration varies among individuals, the height of the coagulation reaction curve differs depending on the test specimen. Accordingly, in the present method, a correction treatment for converting the coagulation reaction curve after the pretreatment into relative values is performed in step 3 c , as needed. With the correction treatment, a coagulation reaction curve that does not depend on the fibrinogen concentration can be obtained, and as a result of which the difference in the shape of the coagulation reaction curve after pretreatment can be quantitatively compared among specimens.
  • the coagulation reaction curve after pretreatment is corrected so that the maximum value is a predetermined value in the correction treatment.
  • a corrected coagulation reaction curve P(t) is determined from the coagulation reaction curve after the pretreatment in accordance with the following formula (1).
  • D(t) represents the coagulation reaction curve after pretreatment
  • Dmax and Dmin represent the maximum value and minimum value of D(t), respectively
  • Drange represents the change width (that is, Dmax ⁇ Dmin) of D(t)
  • A is any value representing the maximum value of the corrected coagulation reaction curve.
  • FIG. 6 shows the data corrected so that the coagulation reaction curve shown in FIG. 4 has a maximum value of 100.
  • the correction treatment may not be necessarily performed.
  • the correction treatment as described above may be performed on a waveform related to the coagulation rate or coagulation acceleration to be described later, or on a parameter group extracted from the waveform.
  • the waveform related to the coagulation rate for the coagulation reaction curve D(t) after pretreatment, to which the correction treatment is not performed is calculated, and then this can be converted into values corresponding to P(t).
  • a parameter group is extracted from the waveform related to the coagulation rate, and then values of individual parameters included in the parameter group can be converted into the values corresponding to P(t).
  • a corrected coagulation reaction curve as described above and a coagulation reaction curve without the correction treatment are also referred to as a corrected zero-order curve and an uncorrected zero-order curve, respectively, and further these are also collectively referred to as “zero-order curve”.
  • primary differential curves of the corrected zero-order curve and the uncorrected zero-order curve are also referred to as a corrected primary curve and an uncorrected primary curve, respectively, and further these are also collectively referred to as “primary curve”.
  • secondary differential curves of the corrected zero-order curve and the uncorrected zero-order curve or primary differential curves of the corrected primary curve and the uncorrected primary curve are also referred to as a corrected secondary curve and an uncorrected secondary curve, respectively, and further these are also collectively referred to as “secondary curve”.
  • a waveform related to the coagulation rate or the coagulation acceleration is calculated.
  • the waveform related to the coagulation rate includes an uncorrected primary curve, and a corrected primary curve.
  • the uncorrected primary curve represents the values obtained by primarily differentiating the coagulation reaction curve (uncorrected zero-order curve), that is, the rate (coagulation rate) of the change in the coagulation reaction amount in an arbitrary coagulation reaction time.
  • the corrected primary curve represents the values obtained by primarily differentiating the corrected coagulation reaction curve (corrected zero-order curve), that is, the relative rate of the change in the coagulation reaction amount in an arbitrary coagulation reaction time.
  • the waveform related to the coagulation rate can be a waveform representing the coagulation rate or the relative value of the coagulation rate, in the coagulation reaction of a sample.
  • a value representing the progress of blood coagulation including the coagulation rate represented by a primary curve and the relative value of the coagulation rate is collectively referred to as a primary differential value.
  • the waveform related to the coagulation acceleration includes an uncorrected secondary curve, and a corrected secondary curve.
  • the values represented by the waveform related to the coagulation acceleration are collectively referred to as a secondary differential value.
  • FIG. 7 shows a corrected primary curve obtained by primarily differentiating the corrected zero-order curve shown in FIG. 6 .
  • the horizontal axis indicates the coagulation reaction time
  • the vertical axis indicates the primary differential value.
  • step 3 e multiple parameters that characterize the waveform related to the coagulation rate or coagulation acceleration of the sample are extracted.
  • the multiple parameters include multiple parameters that characterize the waveform related to the coagulation rate.
  • the multiple parameters include multiple parameters that characterize the waveform related to the coagulation acceleration.
  • the multiple parameters that characterize the waveform related to the coagulation rate, and the multiple parameters that characterize the waveform related to the coagulation acceleration are used in combination.
  • multiple calculation target areas are extracted from the waveform related to the coagulation rate or the coagulation acceleration, and in addition, parameters that characterize these multiple calculation target areas are extracted.
  • multiple parameters that characterize the multiple calculation target areas for the waveform related to the coagulation rate or the coagulation acceleration are extracted.
  • the multiple parameters that characterize the waveform related to the coagulation rate or the coagulation acceleration include multiple parameters that characterize the multiple calculation target areas of the waveform related to the coagulation rate, include multiple parameters that characterize the multiple calculation target areas of the waveform related to the coagulation acceleration, or include the combination of them.
  • a parameter group that contains the obtained multiple parameters is prepared.
  • the parameter group reflects the shape of the waveform related to the coagulation rate or the coagulation acceleration, and is related to the blood coagulation characteristics of a specimen.
  • the parameter group is used for the determination (step 4 ) of a test specimen. The parameters will be described below.
  • the calculation target area is an area (segment) in which the primary differential value (y value) is a predetermined calculation target area level or more in the waveform (primary curve) related to the coagulation rate. More specifically, the calculation target area is an area (segment) in which the primary differential value (y value) is a predetermined calculation target area level or more and a maximum value (Vmax) or less, and further the maximum point of the waveform is included, in the waveform related to the coagulation rate.
  • the calculation target area level is a predetermined value that specifies the lower limit of the calculation target area, and is also referred to as a calculation target area level S in the present specification.
  • the calculation target area level S can be set to limit the range that reflects a peak shape of the waveform related to the coagulation rate. In order to limit the peak shape relatively widely, the calculation target area level S can be set to 0% to 20° of Vmax. In addition, when the calculation target area level S is increased, the influence of the shape of an upper part of the peak relatively largely reflects on the analysis results. In order to analyze the shape of an upper part of the peak, the calculation target area level S can be set to 20% to 95% of Vmax. In one embodiment, the calculation target area level S can be set to 0.5 to 99°, and preferably 5 to 90% of Vmax.
  • multiple calculation target areas are extracted on the basis of multiple different calculation target area levels S.
  • the number of the calculation target areas extracted in the method according to the present invention is not necessarily limited, however, if the number is small, the accuracy of determination of a blood specimen may decrease, and in contrast, if the number is extremely large, the amount of calculation increases and the calculation load increases.
  • the multiple calculation target areas are preferably three or more different areas, more preferably five or more different areas, furthermore preferably 3 to 100 different areas, and still more preferably 5 to 20 different areas.
  • the number of calculation target area levels S corresponds to the number of calculation target areas.
  • the calculation target area levels S for extracting respective calculation target areas are different from each other.
  • the levels S are not close to each other.
  • the distance between the levels S may be set depending on the number of calculation target areas, and is preferably 1/100 or more and 1 ⁇ 2 or less of Vmax, more preferably 1/33 or more and 1 ⁇ 5 or less of Vmax, furthermore preferably 1/20 or more and 1 ⁇ 5 or less of Vmax, and still more preferably 1/20 or more and 1/10 or less of Vmax.
  • the distances between Vmax and respective levels S may be the same as or different from each other.
  • the calculation target area level S can also be applied to a secondary curve.
  • the secondary curve can have peaks in both of the plus and minus directions.
  • the calculation target area level S can be set for each of the plus and minus peaks of the secondary curve.
  • the calculation target area level S can be set to 0.5 to 99%, and preferably 5 to 90% of the maximum value of a plus peak of the secondary curve. In another embodiment, the calculation target area level S can be set to 0.5 to 99%, and preferably 5 to 90% of the minimum value of a minus peak of the secondary curve.
  • the weighted average point (vTx, vHx) corresponds to the “weighted average value” in the calculation target area of F(t).
  • the coagulation reaction time (t) at the weighted average point is defined as the weighted average time vT. That is, the weighted average time vT is a time from the coagulation reaction start time to the weighted average point, and is the x-coordinate of the weighted average point.
  • the weighted average height vH is the y-coordinate of the weighted average point.
  • the weighted average time vT and weighted average height vH for the primary curve can be obtained by the following procedure.
  • Vmax the maximum value of the primary curve F(t)
  • S the calculation target area level
  • the product sum value M is calculated by the following formula (2).
  • the weighted average time vT and the weighted average height vH are calculated by the following formulas (3) and (4), respectively.
  • the weighted average point (vTx, vHx) are led from the obtained vT and vH.
  • S calculation target area level
  • the vT and vH in the calculation target area of which S is 5% are vT5% and vH5%, respectively.
  • These weighted average time vTx and weighted average height vHx can be used as parameters that characterize the calculation target area.
  • FIG. 9 shows the relationship among the calculation target area level S, the areas (calculation target areas) of the corrected zero-order curve and corrected primary curve to be analyzed at that time, and the weighted average point.
  • the left indicates the corrected zero-order curves
  • the right indicates the calculation target areas of the corrected primary curves
  • the black circles indicate the weighted average points.
  • the calculation target area level S changes, the positions of the calculation target area and the weighted average point change as shown in FIG. 9 .
  • FIGS. 8 and 9 parameters related to the calculation target area of the corrected primary curve have been calculated, and the similar parameters can be calculated also for the uncorrected primary curve.
  • the weighted average point, the weighted average time, and the weighted average height can be defined.
  • the secondary curve has peaks in both of the plus and minus directions of the secondary differential value as shown in FIG. 10 .
  • the weighted average point of the secondary curve can be calculated for both of the plus and minus peaks.
  • the time length at which the primary curve is F(t) ⁇ S (value obtained by multiplying the number of data points to be F(t) ⁇ S by the photometric time interval) is defined as the peak width vB of the primary curve.
  • the peak width vB is from the time vTs to the time vTe.
  • the minimum and maximum values of the reaction time at which the secondary differential value at the plus peak of the secondary curve F′(t) is a value of the calculation target area level S or more are pTs and pTe, respectively, and during the time from pTs to pTe, the time length at which F′(t) ⁇ S is obtained (value obtained by multiplying the number of data points to be F′(t) ⁇ S by the photometric time interval) is defined as the peak width pB of the plus peak of the secondary curve.
  • the minimum and maximum values of the reaction time at which the secondary differential value at the minus peak of the secondary curve F′(t) is a value of the calculation target area level S or less are mTs and mTe, respectively, and during the time from mTs to mTe, the time length at which F′(t) ⁇ S is obtained (value obtained by multiplying the number of data points to be F′(t) ⁇ S by the photometric time interval) is defined as the peak width mB of the minus peak of the secondary curve.
  • an area time width vTr can be included.
  • vTr is a width (time length) from vTs to vTe.
  • Other examples of the parameters used in the present invention include a main peak start point time vNs, a main peak end point time vNe, and a main peak width vN.
  • vNs and vNe are parameters for the main peak including the maximum value Vmax in the calculation target area of the primary curve, which are less susceptible to the influence of the noise that may be included in the coagulation reaction curve, as compared with the above vTs, vTe or the like.
  • vNs and vNe have the same values as vTs and vTe, respectively.
  • vN is a width (time length) from vNs to vNe.
  • pNs, pNe, pN, mNs, mNe, and mN can be defined in a similar manner.
  • FIG. 11 shows vTs, vTe, vTr, vNs, vNe, and vN.
  • a weighted average peak width vW can be included.
  • FIG. 12 shows a calculation target area (dotted line) of the primary curve when the calculation target area level S is 10%.
  • a weighted average point (vi, vH) (black circle), vTs, and vTe are shown in the upper part of FIG. 12
  • vB and vW are shown in the lower part of FIG. 12 .
  • vW is a peak width (time length to be F(t) ⁇ vH during the time from the minimum time to the maximum time at which F(t) ⁇ vH is satisfied) at which the primary curve F(t) ⁇ vH is satisfied.
  • the similar parameters can be calculated also for the uncorrected primary curve.
  • the peak width at which F′(t) ⁇ pH is satisfied is defined as the weighted average peak width pW.
  • the width of coagulation reaction time at which F′(t) ⁇ mH is satisfied is defined as the weighted average peak width mW.
  • FIG. 13 shows an average point (vTa, vHa) (white rhombus), a weighted average point (VT, vH) (black circle), vTs, vTe, and vTm of the primary curve when the calculation target area level S is 10%.
  • vTa, vHa, and vTm are represented by the following formulas, respectively when the number of data points from F(vTs) to F(vTe) is denoted by n.
  • vTm vTs + vTe 2 ( 7 )
  • pTm that is the center point of pTs and pTe and mTm that is the center point of mTs and mTe can be obtained by referring to the formula (7).
  • a weighted average height vH, an average height vHa, a peak width vB, and a weighted average peak width vW are used to define flattenings vAB and vABa based on the peak width, and flattenings vAW and vAWa based on the weighted average peak width as the following formulas (8a), (8b), (8c), and (8d), respectively.
  • a weighted average time vT, a peak width vB, and a weighted average peak width vW are used to define a time rate vTB based on the peak width, and a time rate vTW based on the weighted average peak width as the following formulas (9a), and (9b), respectively
  • the flattening and time rate as described above can also be determined for a secondary curve.
  • the flattening pAB based on the peak width, or the flattening pAW based on the weighted average peak width can be determined, and in addition, as the ratio of pT to pB or pW, the time rate pTB based on the peak width, or the time rate pTW based on the weighted average peak width can be determined.
  • the flattening mAB based on the peak width, or the flattening mAW based on the weighted average peak width can be determined, and in addition, as the ratio of mT to mB or mW, the time rate mTB based on the peak width, or the time rate mTW based on the weighted average peak width can be determined.
  • each parameter may be expressed with the calculation target area level S from which it is derived.
  • the parameters that characterize the calculation target area of the primary curve when S is x(%) may be referred to as, for example, vHx, vTx, vBx, and vWx.
  • the parameters vH, vT, vB, vW, vTa, vHa, vTs, vTe, vTm, vTr, vNs, vNe, vN, vAB, vAW, vABa, vAWa, vTB, and vTW which are related to the weighted average point of the primary curve when S is 10%, may be referred to as vH10%, vT10%, vB10%, vW10%, vTa10%, vHa10%, vTs10%, vTe10%, vTm10%, vTr10%, vNs10%, vNe10%, vN10%, vAB10%, vAW10%, vABa10%, vAWa10%, vTB10%, and vTW10%, respectively.
  • FIGS. 14A and 14B show parameters in the cases where the calculation target area level S is different for the same primary curve.
  • FIG. 13A shows the case where the calculation target area level S is 10%
  • FIG. 13B shows the case where the calculation target area level S is 80%.
  • the weighted average height vH10% of the primary curve is 0.4
  • the weighted average time vT10% is 149 seconds
  • the peak width vB10% is 200 seconds.
  • the weighted average height vH80% is 0.72
  • the weighted average time v180% is 119 seconds
  • the peak width vB80% is 78 seconds.
  • the area under the curve (AUC) in the calculation target area of the primary or secondary curve can be included. Since the secondary curve has plus and minus peaks, as the area under the curve (AUC) in the calculation target area, there may be an AUC (pAUC) in the calculation target area for the plus peak, and an AUC (mAUC) in the calculation target area of the minus peak.
  • AUCx in order to identify an AUC derived from a different calculation target area, the AUC may be referred to as AUCx in accordance with the calculation target area level S from which it is derived.
  • the vAUC, pAUC, and mAUC in the calculation target area when S is 5% are vAUC5%, pAUC5%, and mAUC5%, respectively.
  • parameters other than the parameters that characterize the above-described calculation target area may be included in the parameters for the determination of the activity level or activity abnormality of a coagulation factor according to the present invention.
  • the parameters include a maximum primary differential value Vmax, a maximum secondary differential value Amax, a minimum secondary differential value Amin, and VmaxT, AmaxT, and AminT that represent the times to reach them, respectively.
  • the series of parameters described above may include parameters derived from a coagulation reaction curve (corrected zero-order to secondary curves) with correction treatment, and parameters derived from a coagulation reaction curve (uncorrected zero-order to secondary curves) without correction treatment.
  • the signs of F(t) are reversed in the parameter calculation, for example, the maximum value Vmax is replaced with the minimum value Vmin, the calculation target area is an area that satisfies F(t) ⁇ S, vB and vW are time lengths to be F(t) ⁇ x and F(t) ⁇ vH, respectively from t1 to t2.
  • step 4 One example of the determination performed in step 4 will be described.
  • parameters that characterize the calculation target area are extracted.
  • the parameters that characterize the calculation target area include parameters related to the weighted average point of the primary curve (a weighted average time vT, a weighted average height vH, an average time vTa, an average height vHa, a peak width vB, a weighted average peak width vW, flattenings vAB, vAW, vABa, and vAWa determined from them, time rates vTB, and vTW, vAUC, vTs, vTe, vTr, vTm, vNs, vNe, and vN), and parameters related to the weighted average point of the secondary curve (weighted average times pT, and mT, weighted average heights pH, and mH, peak widths pB, and mB,
  • any one or more of these parameters may be extracted, however, a parameter set containing two or more of these parameters may be extracted.
  • the parameters may be at least one selected from the group consisting of vT, vH, vB, vAB, and vTB, however, may be a parameter set containing two or more of these parameters.
  • the parameters are a parameter set containing vT, vH, vB, vAB, and vTB.
  • the parameters are a parameter set containing vB, vAB, and vTB.
  • the parameters are a parameter set containing vB, and vAB.
  • the parameter is pH, pAB, or vH.
  • the parameters are a parameter set of pAB and pNe, a parameter set of pTW and vT, a parameter set of pTB and vABa, a parameter set of pAB and vNs, or a parameter set of pTW, vTs, and vW.
  • the constitution of the parameters that characterize each of the calculation target areas used in the method according to the present invention is not limited to these embodiments.
  • the multiple parameters (parameter group) used for the determination of a test specimen in the method according to the present invention include multiple parameters that characterize the multiple calculation target areas, respectively of one waveform.
  • the parameter group is a set of multiple parameters that are extracted from multiple calculation target areas of one waveform.
  • the parameter group includes one or more sets of the same kind of parameters extracted from different calculation target areas of one waveform (primary curve or secondary curve). For example, in a case where L areas of calculation target areas are extracted and the parameter to be adopted is vHx, the parameter group is formed of L pieces of vHx.
  • the parameter group is a set of 10 pieces of vHx [vH5%, vH10%, vH20%, vH30%, vH40%, vH50%, vH60%, vH70%, vH80%, and vH90%].
  • the parameter group is a set of 5 pieces of vHx [vH5%, vH20%, vH40%, vH60%, and vH80%].
  • the parameter group is formed of M sets of [vBx, vABx, and vTBx].
  • the parameter group is formed of N sets of [vTx, vHx, vBx, vABx, and vTBx].
  • multiple parameters that characterize each of the calculation target areas may be combined with other parameters. For example, at least one selected from the group consisting of a maximum primary differential value Vmax, a maximum secondary differential value Amax, a minimum secondary differential value Amin, and VmaxT, AmaxT, and AminT that represent the times to reach them, respectively, which are shown in Table A to be described later, may be combined with the multiple parameters that characterize the above calculation target area.
  • the blood coagulation time prolongation factor component to be targeted of which the activity level or activity abnormality is determined by the method according to the present invention, any endogenous or exogenous component involved in coagulation reaction, which causes a prolongation of blood coagulation time, is included.
  • the blood coagulation time prolongation factor component to be targeted is a coagulation factor.
  • the coagulation factor is preferably at least one kind selected from coagulation factors including FVIII and FIX, and more preferably at least FVIII. Both of FVIII and FIX may be targeted.
  • a parameter group (hereinafter, also referred to as test parameter group) that includes multiple parameters extracted from multiple calculation target areas of a waveform related to the coagulation rate or coagulation acceleration of the above-described test specimen is compared with a corresponding parameter group (also referred to as template parameter group in the present specification) for a template blood specimen (hereinafter, also simply referred to as template specimen).
  • coagulation characteristics of the test specimen preferably the activity level or activity abnormality of a blood coagulation time prolongation factor component in the test specimen is determined.
  • one or more of template specimens are prepared.
  • the template specimen is a blood specimen in which the activity level or the presence or absence of activity abnormality, of a blood coagulation time prolongation factor component to be targeted in the method according to the present invention is known.
  • the one or more of template specimens include one or more of blood specimens with a non-abnormal FVIII activity level (normal FVIII specimens), and one or more of blood specimens with an abnormal FVIII activity level (abnormal FVIII specimens, for example, FVIII-deficient specimens).
  • the one or more of template specimens include one or more of blood specimens with a non-abnormal FIX activity level (normal FIX specimens), and one or more of blood specimens with an abnormal FIX activity level (abnormal FIX specimens, for example, FIX-deficient specimens).
  • the one or more of template specimens include one or more of blood specimens with non-abnormal FVIII and FIX activity levels (normal FVIII/FIX specimens), one or more of blood specimens with an abnormal FVIII activity level (abnormal FVIII specimens, for example, FVIII-deficient specimens), and one or more of blood specimens with an abnormal FIX activity level (abnormal FIX specimens, for example, FIX-deficient specimens).
  • the abnormal FVIII specimens include blood specimens derived from patients with severe, moderate, and mild hemophilia A.
  • the blood specimens derived from patients with severe, moderate, and mild hemophilia A are blood specimens having FVIII activities of less than 1%, 1% or more and less than 5%, and 5% or more and less than 40%, respectively (when the activity of normal individual is taken as 100%, the same applies hereinafter).
  • multiple specimens derived from patients with severe hemophilia A having different FVIII activity levels may be prepared as needed.
  • a specimen derived from a patient with Modestly-Severe Haemophilia A (MS-HA) having a FVIII activity of 0.2% or more and less than 1%, and a specimen derived from a patient with Very-Severe Haemophilia A (VS-HA) having a FVIII activity of less than 0.2% may be prepared.
  • the abnormal FIX specimens preferably include blood specimens derived from patients with severe, moderate, and mild hemophilia B.
  • the specimens derived from the patients with severe, moderate, and mild hemophilia B are specimens having FIX activities of less than 1%, 1% or more and less than 5%, and 5% or more and less than 40%, respectively (when the activity of normal individual is taken as 100%, the same applies hereinafter).
  • multiple specimens derived from patients with severe hemophilia B having different FIX activity levels may be prepared as needed. For example, a specimen having a FIX activity of 0.2% or more and less than 1%, and a specimen having a FIX activity of less than 0.2% may be prepared.
  • a regression analysis of the corresponding parameters is performed between the test parameter group and the template parameter group derived from each template specimen.
  • the template parameter group used for the regression analysis is obtained by performing the data analysis described in the above 1.3. for each template specimen.
  • the number of calculation target areas to be extracted, and a series of calculation target area levels S used for the extraction of multiple calculation target areas are set to the same values as those of the data analysis of the test specimen.
  • the kinds of the parameters included in the template parameter group are the same as those of the test parameter group. For example, if the test parameter group is L pieces of vHx, the template parameter group for the template specimen is also L pieces of vHx.
  • the template parameter group for the template specimen is also M sets of [vBx, vABx, and vTBx].
  • the template parameter group for the template specimen is also N sets of [vTx, vHx, vBx, vABx, and vTBx].
  • the template parameter group is a parameter group for the template specimen corresponding to the test parameter group. That is, the individual parameters included in each template parameter group correspond to the individual parameters included in the test parameter group mutually.
  • the parameters of the template parameter group correspond to the parameters of the test parameter group
  • the parameters of the template parameter group and the parameters of the test parameter group are the same kind of parameters.
  • the vTx, vHx, vBx, vABx and vTBx of the test parameter group correspond to the vTx, vHx, vBx, vABx and vTBx (x is a predetermined value) of the template parameter group, respectively.
  • the template parameter group consisting of parameters that correspond to all the parameters of the test parameter group corresponds to the test parameter group.
  • each template parameter group may be a synthesis parameter group obtained by processing a parameter group that has been obtained from multiple template specimens. For example, by acquiring parameter groups for multiple template specimens having the same activity levels of a target blood coagulation time prolongation factor component, and statistically processing the parameter groups, one or more of synthesis parameter groups representing standard template specimens may be prepared.
  • the technique of the regression analysis is not particularly limited, and includes, for example, linear regression by a method of least squares.
  • the value of each parameter in the test parameter group is plotted on the y-axis, and the value of the corresponding parameter in any one template parameter group is plotted on the x-axis to obtain a regression line.
  • the correlation between the test parameter group and the template parameter group is examined on the basis of the tilt of the regression line, the intercept, the correlation (for example, correlation coefficient, or determination coefficient), or the like.
  • the correlation between the test parameter group and the template parameter group reflects the correlation (approximate state) of the coagulation characteristics between the test specimen and the template specimen from which the template parameter group is derived.
  • the coagulation characteristics in a test specimen are determined.
  • the determination of the coagulation characteristics is a determination of the activity level or the activity abnormality, of a blood coagulation time prolongation factor component to be targeted.
  • the determination procedure will be described by taking the case where the blood coagulation time prolongation factor component to be targeted is FVIII as an example. Other factors such as FIX may be determined by the similar procedure.
  • the FVIII activity level or activity abnormality (for example, deficiency) of the test specimen is determined.
  • the correlation is correlation (for example, tilt, intercept, correlation coefficient, or determination coefficient) of the regression line.
  • a template specimen includes one or more of normal FVIII specimens, and one or more of abnormal FVIII specimens having variously different FVIII activity levels.
  • the template specimen includes one or more of normal FVIII specimens, and one or more of the abnormal FVIII specimens derived from patients with severe (VS-HA and MS-HA as needed), moderate, and mild hemophilia A. From all of the template specimens used in the regression analysis, at least one specimen with which the correlation between the test parameter group and the template parameter group satisfies predetermined conditions is selected.
  • a template specimen with which the correlation is a value of the threshold that has set in advance or more is selected. In another embodiment, a template specimen with which the correlation is a value equal to or more than the threshold that has set in advance and is the highest is selected. In another embodiment, a template specimen with which the tilt of the regression line between the test parameter group and the template parameter group is in a predetermined range (for example, 0.70 or more and 1.30 or less, preferably 0.75 or more and 1.25 or less, more preferably 0.80 or more and 1.20 or less, furthermore preferably 0.85 or more and 1.15 or less, and still more preferably 0.87 or more and 1.13 or less) is selected.
  • a predetermined range for example, 0.70 or more and 1.30 or less, preferably 0.75 or more and 1.25 or less, more preferably 0.80 or more and 1.20 or less, furthermore preferably 0.85 or more and 1.15 or less, and still more preferably 0.87 or more and 1.13 or less
  • a template specimen with which the tilt of the regression line between the test parameter group and the template parameter group is in the predetermined range and further the correlation coefficient of the regression line is a predetermined value or more is selected.
  • the template specimen may be selected again by changing the predetermined conditions, or such a case may be evaluated as “no template specimen selection”.
  • a template specimen with which the tilt of the regression line is in a predetermined range (for example, 0.70 or more and 1.30 or less, preferably 0.75 or more and 1.25 or less, more preferably 0.80 or more and 1.20 or less, furthermore preferably 0.85 or more and 1.15 or less, and still more preferably 0.87 or more and 1.13 or less) is selected.
  • a template specimen with which the tilt of the regression line is in the predetermined range and further the correlation coefficient of the regression line is a predetermined value or more is selected. From the selected template specimens, a template specimen with which the correlation coefficient of the regression is the highest is selected. In a case where multiple template specimens satisfying the predetermined conditions are selected, one template specimen may be selected on the basis of additional criteria from them.
  • the state of FVIII (that is, activity level or activity abnormality of FVIII) in the selected template specimen is determined as the state of FVIII in the test specimen.
  • the state of FVIII in the test specimen may be determined to be corresponded to any of the states of the multiple template specimens, or the average state of the multiple template specimens may be determined as the state of FVIII in the test specimen.
  • the selected template specimen is a normal FVIII specimen
  • the state of FVIII in the test specimen can be determined to be not abnormal
  • the selected template specimen is an abnormal FVIII specimen
  • the test specimen can be determined to have abnormality of the FVIII activity.
  • the selected template specimens are specimens derived from patients with severe, moderate, and mild hemophilia A
  • the test specimens can be determined to be severe, moderate, and mild hemophilia A, respectively.
  • the test specimen can be determined to be VS-HA or MS-HA.
  • the FVIII activity level of the selected template specimen can be determined as the FVIII activity level in the test specimen.
  • the template specimens include specimens derived from patients with severe, moderate, and mild hemophilia A and have “no template specimen selection” in the above evaluation for correlation, it can be determined that the test specimen does “not have the activity abnormality of FVIII”, or that “the prolongation factor of the blood coagulation time is not due to the activity abnormality of FVIII” of the test specimen.
  • template specimens with each of which the tilt of the regression line is in a predetermined range are all selected.
  • template specimens with each of which the tilt of the regression line is in the predetermined range and further the correlation coefficient of the regression line is a predetermined value or more are all selected.
  • the state of FVIII that is, activity level or activity abnormality of FVIII, which is most frequently found in the selected template specimens, is determined as the state of FVIII in the test specimen.
  • the state of FVIII in the test specimen can be determined to be not abnormal.
  • the test specimen can be determined to have abnormality of the FVIII activity.
  • the test specimens can be determined to be severe, moderate, and mild hemophilia A, respectively.
  • the test specimens can be determined to be VS-HA and MS-HA, respectively.
  • the test specimens can be determined to be abnormal specimens other than the specimens derived from patients with (severe, moderate, and mild) hemophilia A.
  • the FVIII activity level in the test specimen is determined, the FVIII activity level that is most frequently found in the selected template specimens can be determined as the FVIII activity level in the test specimen.
  • template specimens with each of which the tilt of the regression line is in a predetermined range are all selected.
  • template specimens with each of which the tilt of the regression line is in the predetermined range and further the correlation coefficient of the regression line is a predetermined value or more are all selected.
  • the selected template specimens are classified into specimens derived from patients with (severe, moderate, and mild) hemophilia A having a low FVIII activity and other specimens, in accordance with the FVIII activity level.
  • the severity either one of severe, moderate, or mild
  • the test specimen can be determined to be a specimen other than those of patients with (severe, moderate, and mild) hemophilia A.
  • the FVIII activity level or the presence or absence of the activity abnormality, in the test specimen can be determined by the method according to the present invention.
  • the presence or absence of the activity abnormality of FVIII in the test specimen is determined, and the determination provides the information about the determination of whether or not the test specimen is a specimen of a patient with hemophilia A.
  • the FVIII activity level in the test specimen is determined, and the determination provides the information about the determination of the severity of hemophilia A in a patient who has provided the test specimen.
  • one embodiment of the method for analyzing a blood specimen according to the present invention can be a method for, for example, determining hemophilia A, and determining the severity of hemophilia A such as severe (VS-HA or MS-HA if necessary), moderate, or mild.
  • the determination on other blood coagulation time prolongation factor components may be performed for the test specimen.
  • one of other blood coagulation time prolongation factor components is FIX.
  • the prolongation factor of the blood coagulation time is not due to the activity abnormality of FVIII” or determined to be “other than those of patients with (severe, moderate, and mild) hemophilia A” in the above determination on FVIII, the activity level or the presence or absence of the activity abnormality, of FIX may be determined.
  • the determination procedure of the activity level or the presence or absence of the activity abnormality, of FIX can be performed by a procedure similar to the above-described determination procedure for FVIII.
  • the template specimens used for the determination of the FIX may be the same as or different from those used in the evaluation for FVIII.
  • the test parameter group and template parameter group used for the determination on FIX may be the same as or different from those used in the determination on FVIII.
  • the presence or absence of the activity abnormality of FIX in the test specimen is determined, and the determination provides the information about the determination of whether or not the test specimen is a specimen of a patient with hemophilia B.
  • the FIX activity level in the test specimen is determined, and the determination provides the information about the determination of the severity of hemophilia B in a patient who has provided the test specimen.
  • the present embodiment enables the determination of hemophilia B, and the determination of the severity (for example, severe, moderate, or mild) of hemophilia B.
  • the coagulation characteristics in the test specimen can be analyzed more comprehensively.
  • the above-described method for analyzing a blood specimen according to the present invention can be performed automatically by using a computer program. Accordingly, one embodiment of the present invention is a program for performing the above-described method for analyzing a blood specimen according to the present invention. Further, a series of steps of the above-described method according to the present invention, including preparation of a sample from a test specimen and measurement of coagulation time can be performed automatically by an automatic analyzer. Therefore, one embodiment of the present invention is an apparatus for performing the above-described method for analyzing a blood specimen according to the present invention.
  • the automatic analyzer 1 includes a control unit 10 , an operation unit 20 , a measurement unit 30 , and an output unit 40 .
  • the control unit 10 controls the overall operations of the automatic analyzer 1 .
  • the control unit 10 can be configured by, for example, a personal computer (PC).
  • the control unit 10 includes, for example, a central processing unit (CPU), a memory, a storage, and a communication interface (I/F), and performs, for example, processing of commands from the operation unit 20 , control of operation of the measurement unit 30 , storage and data analysis of measurement data received from the measurement unit 30 , storage of the analysis results, and control of output of the measurement data and the analysis results by the output unit 40 .
  • the control unit 10 may be connected to other devices such as an external medium, and a host computer.
  • the PC that controls the operation of the measurement unit 30 and the PC that analyzes the measurement data may be the same or different.
  • the operation unit 20 acquires input from an operator, and transmits the obtained input information to the control unit 10 .
  • the operation unit 20 includes a user interface (UI) such as a keyboard, and a touch panel.
  • UI user interface
  • the output unit 40 outputs the measurement data of the measurement unit 30 , and the analysis results of the data under the control of the control unit 10 .
  • the output unit 40 includes a display device such as a display.
  • the measurement unit 30 performs a series of operations for the blood coagulation test, and acquires measurement data of coagulation reaction of a sample containing a blood specimen.
  • the measurement unit 30 includes various kinds of equipment and analysis modules, which are required for a blood coagulation test, for example, a specimen container for storing a blood specimen, a reagent container for storing a test reagent, a reaction vessel for reaction of a specimen with a reagent, a probe for dispensing a blood specimen and a reagent into the reaction vessel, a light source, a detector for detecting scattered light or transmitted light from a sample in the reaction vessel, a data processing circuit for sending data from the detector to the control unit 10 , and a control circuit for controlling operation of the measurement unit 30 in response to a command from the control unit 10 .
  • the control unit 10 performs the analysis of coagulation characteristics of a specimen on the basis of the data measured by the measurement unit 30 .
  • the present analysis can include, for example, acquisition of the above-described coagulation reaction curve, and a waveform related to the coagulation rate or the coagulation acceleration, extraction of a parameter group for a test specimen, extraction of a template parameter group for a template specimen, regression analysis of the parameter groups, and determination of the activity level or activity abnormality of a blood coagulation time prolongation factor component to be targeted in the test specimen based on the results of the regression analysis.
  • the present analysis can be performed by a program for performing the method according to the present invention. Accordingly, the control unit 10 can include a program for performing the method according to the present invention.
  • the coagulation reaction curve, and the waveform related to the coagulation rate or the coagulation acceleration may be prepared in the control unit 10 on the basis of the measurement data from the measurement unit 30 , or may be prepared by another device, for example, the measurement unit 30 , and sent to the control unit 10 .
  • the coagulation reaction curve may be prepared in the measurement unit 30 , and sent to the control unit 10
  • the waveform related to the coagulation rate or the coagulation acceleration may be prepared in the control unit 10 .
  • the data of the template parameter group for a template specimen may be prepared by measuring the template specimen in advance in the measurement unit 30 , and analyzing the obtained measurement data in the control unit 10 , or may be taken in from the outside.
  • the data of the template parameter group can be stored in a memory of the control unit 10 or an external device.
  • the technique of the regression analysis, and the determination criteria for analyzing the coagulation characteristics of the test specimen based on the results of the regression analysis can be controlled by the program according to the present invention.
  • the analysis results in the control unit 10 are sent to the output unit 40 , and output.
  • the output can take any form of, for example, display on a screen, transmission to a host computer, or printing.
  • the output information from the output unit includes the determination results of a blood coagulation time prolongation factor component to be targeted in a test specimen (determination results of, for example, FVIII activity level, hemophilia A, or the severity of hemophilia A), and, if desired, may include additional information such as results (for example, regression line equation, and correlation) of the regression analysis of a test specimen and a template specimen, a coagulation reaction curve of the test specimen or the template specimen, or a waveform related to the coagulation rate or the coagulation acceleration.
  • the kind of the output information from the output unit can be controlled by the program according to the present invention.
  • an automatic analyzer 1 can have a configuration of a common automatic analyzer for blood coagulation test as conventionally used for measuring a blood coagulation time such as APTT, or PT.
  • the parameters used in the following Examples represent parameters derived from corrected zero-order to secondary curves.
  • the parameters derived from uncorrected zero-order to secondary curves are represented by adding R to the beginning of the name of each parameter.
  • RvH the weighted average height of the uncorrected primary curve
  • RpH the weighted average height of the uncorrected secondary curve
  • Coagpia APTT-N (manufactured by Sekisui Medical Co., Ltd.) being a reagent for APTT measurement was used, and as a calcium chloride solution, a calcium chloride solution, Coagpia APTT-N (manufactured by Sekisui Medical Co., Ltd.) was used.
  • the coagulation reaction measurement of a sample containing a specimen was performed by using a blood coagulation automatic analyzer, CP3000 (manufactured by Sekisui Medical Co., Ltd.). In a cuvette, 50 ⁇ L of a reagent for measurement at around 37° C.
  • the cuvette was irradiated with light having a wavelength of 660 nm using a light-emitting diode (LED) as a light source, and the amount of scattered light of 90-degree side scattered light was measured at 0.1-second intervals.
  • the measurement time was set to 360 seconds.
  • a coagulation reaction curve was obtained from the obtained measurement data over time.
  • 34 specimens blood plasma were analyzed.
  • FVIII ⁇ 1° specimens of severe severity
  • a corrected primary curve was calculated from the coagulation reaction curve derived from a test specimen, which was obtained in (2).
  • the coagulation reaction curve was pretreated. That is, a smoothing treatment including noise removal was performed for the coagulation reaction curve, and the amount of scattered light at the starting point of the measurement was adjusted to 0. Subsequently, the maximum height of the coagulation reaction curve was corrected so as to be 100, and the obtained corrected coagulation reaction curve (corrected zero-order curve) was primarily differentiated to calculate a corrected primary curve.
  • the calculation target area levels S were set to 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90%, respectively with respect to the maximum height value Vmax (100%) of the corrected primary curve.
  • the peak width vB and by using the above-described formulas (2), (3), and (4), the weighted average time vT and the weighted average height vH were calculated. From the determined vT and vH, the flattening vAB and the time rate vTB were calculated by the following formulas.
  • test parameter groups were prepared as follows:
  • (Parameter group A-1) a parameter group consisting of 50 parameters of vB [vB5%, vB10%, . . . , and vB90%], vT [vT5%, vT10%, . . . , and vT90%], vH [vH5%, vH10%, . . . , and vH90%], vAB [vAB5%, vAB10%, . . . , and vAB90%], and vTB [vTB5%, vTB10%, . . . , and vTB90%];
  • (Parameter group A-2) a parameter group consisting of 30 parameters of vB [vB5%, vB10%, . . . , and vB90%], vAB [vAB5%, vAB10%, . . . , and vAB90%], and vTB [vTB5%, vTB10%, . . . , and vTB90%]; and
  • (Parameter group A-3) a parameter group consisting of 20 parameters of vB [vB5%, vB10%, . . . , and vB90%], and vAB [vAB5%, vAB10%, . . . , and vAB90%].
  • test parameter groups were prepared as follows:
  • Parameter group A-4 a parameter group consisting of 54 parameters of Vmax, Amax, VmaxT, and AmaxT in addition to the parameters of the parameter A-1;
  • Comparison parameter group 1 a parameter group consisting of 4 parameters of Vmax, Amax, VmaxT, and AmaxT.
  • test parameter groups were prepared as follows:
  • (Parameter group B-1) a parameter group consisting of 25 parameters of vB [vB5%, vB20%, vB40%, vB60%, and vB80%], vT [vT5%, vT20%, vT40%, vT60%, and vT80%], vH [vH5%, vH20%, vH40%, vH60%, and vH80%], vAB [vAB5%, vAB20%, vAB40%, vAB60%, and vAB80%], and vTB [vTB5%, vTB20%, vTB40%, vTB60%, and vTB80%];
  • (Parameter group B-2) a parameter group consisting of 15 parameters of vB [vB5%, vB20%, vB40%, vB60%, and vB80%], [vAB5%, vAB20%, vAB40%, vAB60%, and vAB80%], and vTB [vTB5%, vTB20%, vTB40%, vTB60%, and vTB80%];
  • (Parameter group B-3) a parameter group consisting of 10 parameters of vB [vB5%, vB20%, vB40%, vB60%, and vB80%], and vAB [vAB5%, vAB20%, vAB40%, vAB60%, and vAB80%]; and
  • Parameter group B-4 a parameter group consisting of 29 parameters of Vmax, Amax, VmaxT, and AmaxT in addition to the parameters of the parameter B-1.
  • FIG. 16 shows the results of the top 5 cases in descending order of the correlation coefficient among the results of regression analysis with a test specimen derived from a patient with severe hemophilia A (VS-HA) having a FVIII activity of less than 0.2% (Sample AF, APTT time: 118.1 seconds, and FVIII ⁇ 0.2%). Further, the labels on the horizontal axis and the vertical axis of each diagram in FIG. 16 indicate the FVIII activity and APTT time of template and test specimens, respectively.
  • the correlation coefficient of these 5 cases was 0.98 or more, the presence of a template specimen having a high correlation with respect to the parameter group with the test specimen Sample AF was confirmed.
  • the 5 selected template specimens are all specimens derived from patients with VS-HA having a FVIII activity of less than 0.2%.
  • FIG. 17A shows a regression line with the specimen (Template A) having the highest correlation coefficient in FIG. 16 .
  • FIG. 17B shows corrected primary curves of the test specimen (Sample AF) and Template A.
  • the corrected primary curves of the test specimen (Sample AF) and Template A have extremely similar shapes, and it was indicated that the blood coagulation characteristics of both specimens were similar. From these results, it was revealed that the present analysis was able to be used for the determination of the FVIII activity in a blood specimen. Further, it was revealed that the present analysis was effective also in the detection of a specimen of a patient with VS-HA.
  • the regression analysis was performed between 34 test specimens and each template specimen.
  • Linear regression equations for a parameter group were determined between the test specimen and all the template specimens, and template specimens having a tilt of the regression line in the range of from 0.87 to 1.13 were selected from them.
  • a template specimen having the highest correlation coefficient was selected as the template specimen having the highest correlation from the selected template specimens.
  • the FVIII activity of the selected template specimen was determined as the FVIII activity of the test specimen.
  • the FVIII activity level of a test specimen was classified into 4 stages (FVIII activities: ⁇ 1%, 1 to 5%, 5 to 40%, and Other).
  • the FVIII activity level concordance rate indicates a ratio at which the FVIII activity level of a test specimen by determination was matched with the actual FVIII activity level of the test specimen
  • the FVIII-deficient concordance rate indicates a ratio at which the presence or absence of FVIII deficiency of a test specimen by determination was matched with the actual presence or absence of FVIII deficiency of the test specimen.
  • FVIII activity level concordance rate (%) ( A 11+ A 22 +A 33+ A 44)/ D ⁇ 100
  • FVIII activity level (determined) ⁇ 1% 1-5% 5-40% Other Total FVIII activity level ⁇ 1% A11 A12 A13 A14 B1 (actually measured) 1-5% A21 A22 A23 A24 B2 5-40% A31 A32 A33 A34 B3 Other A41 A42 A43 A44 B4 Total C1 C2 C3 C4 D
  • Tables 3 to 5 are comparison tables between the determined FVIII activity of a test specimen and the actual FVIII activity of the test specimen. Comparison tables in a case where parameter groups A-1 to A-4 were used are shown in Table 3, comparison tables in a case where parameter groups B-1 to B-4 were used are shown in Table 4, and a comparison table in a case where a comparison parameter group 1 was used is shown in Table 5.
  • Evaluation criteria 1 for correlation Linear regression equations for the parameter groups between all the template specimens and the test specimens were determined, template specimens having a tilt of the regression line in the range of from 0.87 to 1.13 were selected, and a template specimen with which the correlation coefficient was the highest was selected from the selected template specimens (the same evaluation criteria as in Example 2).
  • Evaluation criteria 2 for correlation Linear regression equations for the parameter groups between all the template specimens and the test specimens were determined, a template specimen with which the correlation coefficient was the highest was selected.
  • Table 7 Table 7-1 is the same as Table 3A-4.
  • Table 8 The kinds of the parameters used in the analysis, the FVIII-deficient concordance rates, and the FVIII activity level concordance rates are summarized in Table 8.
  • FIX activity level was able to be determined with a high concordance rate.
  • the 46 plasma specimens of patients having a decreased FVIII activity or FIX activity were used as the subject blood specimen.
  • a mixed plasma obtained by mixing a commercially available coagulation factor-deficient plasma with a lupus anticoagulant (LA) or normal plasma in various proportions, and a FVIII-added plasma obtained by adding a FVIII preparation into a commercially available FVIII-deficient plasma were used.
  • LA lupus anticoagulant
  • FVIII-added plasma obtained by adding a FVIII preparation into a commercially available FVIII-deficient plasma
  • the coagulation factor-deficient plasma and the LA plasma Factor VIII Deficient Plasma, Factor IX Deficient Plasma, Factor V Deficient Plasma, Factor X Deficient Plasma, Factor XI Deficient Plasma, Factor XII Deficient Plasma, Prekallikrein Deficient Plasma, or Positive Lupus Anticoagulant Plasma (all of which are manufactured by George King Bio-Medical, Inc.) were used.
  • FVIII preparation a gene recombinant blood coagulation factor VIII preparation, ADVATE (manufactured by Shire Japan KK) was used.
  • normal plasma a normal pool plasma in which the concentration of each factor can be regarded as 100% was used.
  • mixed plasmas having a factor concentration of 0.25%, 0.5, 0.75%, 1%, 2.5%, 5%, 10%, 25%, and 50%, respectively were prepared.
  • FVIII-added plasmas having a FVIII concentration of 0.625%, 1.25%, 2.5%, 5%, 10%, 20%, 40%, 80%, and 160%, respectively were prepared.
  • FVIII-added plasmas having a FVIII concentration of 0.3%, 0.6%, 1%, 2%, 4%, 8%, 16%, 32%, 64%, and 128%, respectively were prepared.
  • 143 template specimens in total of 59 FVIII-activity abnormal specimens, 80 factor-deficient specimens each having a normal FVIII activity but reduced other coagulation factors, and 4 LA-positive specimens were prepared.
  • the remaining 84 specimens belonged to “Other” because the FVIII activity was not abnormal.
  • test specimens were specimens either from a FVIII-deficient patient (hemophilia A) or from a FIX-deficient patient (hemophilia B), and the template specimens were prepared on the basis of a commercially available factor-deficient plasma or a LA-positive plasma without using any specimen from a patient with hemophilia A or hemophilia B.
  • the conditions were set so that it was difficult to correctly determine the state of the coagulation factor of the test specimen, as compared with Example 2.
  • Constitutions of the test specimens and template specimens used in the present Example are shown in Table 11.
  • Example 2 In accordance with the procedure of (1) in Example 1, a coagulation reaction curve for each of the test specimens and template specimens was obtained. The distributions of the FVIII activity and APTT for the test specimens and template specimens are shown in FIG. 18 .
  • an uncorrected primary curve, an uncorrected secondary curve, a corrected primary curve, and a corrected secondary curve were calculated from a coagulation reaction curve.
  • 10 areas of calculation target areas based on 10 levels of calculation target area levels S (5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% of the maximum height of the curve) were extracted, and the parameters characterizing each calculation target area were acquired.
  • the maximum values of a curve being conventional parameters and the times to reach the maximum values (Vmax, RVmax, VmaxT, Amax, RVmax, and AmaxT) were acquired. The acquired parameters are shown in Table 12.
  • a parameter group was prepared from the parameters shown in Table 12.
  • a parameter “vHx” a set of [vH5%, vH10%, vH20%, vH30%, vH40%, vH50%, vH60%, vH70%, vH80%, and vH90%] was used as the parameter group.
  • the same parameter group as in the comparative example of Example 2 was used.
  • the FVIII activity or abnormality of a test specimen was determined by a regression analysis using the parameter group.
  • a primary regression analysis was performed between the test parameter group obtained from a test specimen, and the corresponding template parameter group obtained from each template specimen.
  • Template specimens with each of which the tilt of the primary regression equation obtained by the regression analysis was within 1 ⁇ 0.15 and the correlation coefficient of the primary regression equation was larger than 0.90 were extracted.
  • a template specimen having the largest correlation coefficient among the extracted template specimens was selected. In a case where multiple specimens that have the same correlation coefficient were present, a template specimen having a tilt of the regression equation closer to 1 was selected.
  • the FVIII-deficient concordance rate and the FVIII activity level concordance rate were calculated by a procedure similar to that in Example 2.
  • the parameter groups used, and the obtained FVIII-deficient concordance rates and FVIII activity level concordance rates are shown in Tables 13 and 14.
  • the parameter with the highest (63.0%) FVIII-deficient concordance rate was the parameter pHx of the secondary curve.
  • the parameter with the highest (76.1%) FVIII activity level concordance rate was the parameter mTx of the secondary curve.
  • the heights of the FVIII-deficient concordance rate and the FVIII activity level concordance rate were not correlated with each other.
  • the FVIII-deficient concordance rate was 52.2% in a case where conventional parameters (combination of VmaxT, AmaxT, Vmax, and Amax) were used.
  • VT a combination of parameters “VT” and “vB” was used, a combination of a set of [vT5%, vT10%, vT20%, vT30%, vT40%, vT50%, vT60%, vT70%, vT80%, and vT90%] and a set of [vB5%, vB10%, vB20%, vB30%, vB40%, vB50%, vB60%, vB70%, vB80%, and vB90%] was used as a parameter group.
  • the combination parameter groups with high FVIII-deficient concordance rates, and the obtained FVIII-deficient concordance rates and FVIII activity level concordance rates are shown in Tables 15 and 16.
  • the results in a case of a combination of 2 kinds of parameters are shown in Table 15, and the results in a case of a combination of 3 kinds of parameters are shown in Table 16.
  • the results of a parameter group (pNs_pNe_vTB) with the highest FVIII activity level concordance rate are also shown in Table 16.
  • Example 5 By using the specimens used in Example 5, a primary regression analysis was performed between the test parameter group and the template parameter group by a procedure similar to that in Example 5. Next, in accordance with the following different determination criteria, the state of the FVIII activity of the test specimen was determined.
  • Example 5 the state of the FVIII activity in a template specimen having the largest correlation coefficient among the template specimens with each of which the tilt of the primary regression equation was within 1 ⁇ 0.15 and the correlation coefficient of the regression equation was larger than 0.90 was determined as the state of the FVIII activity of the test specimen.
  • the test specimen was determined to be Other.
  • a state severe, moderate, or mild
  • a more severe state was determined as the state of the test specimen.
  • the state of the test specimen was determined as Other.
  • the FVIII activity of the template specimen of ⁇ 1> in the correlation coefficient ranking was matched with the determination result based on determination criteria 1.
  • combination parameter groups were prepared by arbitrarily combining three kinds of parameters that characterize 55 kinds of calculation target areas shown in Table 12.
  • a primary regression analysis which was used between the test parameter group and the template parameter group, was performed, and then a state of the FVIII activity of the test specimen was determined in accordance with determination criteria 1 to 3.
  • the FVIII-deficient concordance rate or the FVIII activity level concordance rate was calculated by a procedure similar to that in Example 2. Further, the average (average concordance rate) of the FVIII-deficient concordance rates or the FVIII activity level concordance rates was calculated.
  • Table 20 shows the number of combination parameter groups that achieved the level of the concordance rate.
  • the bottom line of Table 20 shows the maximum values of the concordance rate based on each of the determination criteria.
  • the FVIII-deficient concordance rate was 78.3% at most based on any of the criteria.
  • the number of combination parameter groups that satisfy the maximum concordance rate level (exceeding 75% to 80% or less) was 12 based on determination criteria 1, and 17 based on each of determination criteria 2 and 3.
  • the FVIII activity level concordance rate was 91.3% at most based on any of the criteria.
  • the number of parameter groups that satisfy the maximum concordance rate level was one based on each of determination criteria 1 and 3, and two based on determination criteria 2.
  • the maximum value of the average concordance rate was 81.5% based on determination criteria 1, and 84.8% based on each of determination criteria 2 and 3.
  • the number of parameter groups that satisfy the maximum concordance rate level was 9 based on determination criteria 1, and 13 based on each of determination criteria 2 and 3.
  • a state of the FVIII activity of the test specimen was determined in accordance with determination criteria 1 to 3, by changing the allowable tilt range and correlation coefficient threshold in the primary regression equation.
  • the parameter group a combination parameter group of pTW_vTs_vW, which showed the highest FVIII-deficient concordance rate and FVIII activity level concordance rate in Example 5, was used.
  • the tilt of the primary regression equation was changed from 1 ⁇ 0.05 to 1 ⁇ 0.25 (that is, allowable range of from 0.05 to 0.25) in a stepwise manner.
  • the threshold of the correlation coefficient was changed from >0.75 to >0.98 in a stepwise manner.
  • the FVIII-deficient concordance rate and the FVIII activity level concordance rate were calculated under each condition. The results are shown in FIGS. 19 to 21 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US17/427,000 2019-01-31 2020-01-31 Method for analyzing blood coagulation characteristics of blood specimen Pending US20220146537A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019016474 2019-01-31
JP2019-016474 2019-01-31
PCT/JP2020/003796 WO2020158948A1 (ja) 2019-01-31 2020-01-31 血液検体の血液凝固特性の分析方法

Publications (1)

Publication Number Publication Date
US20220146537A1 true US20220146537A1 (en) 2022-05-12

Family

ID=71841047

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/427,000 Pending US20220146537A1 (en) 2019-01-31 2020-01-31 Method for analyzing blood coagulation characteristics of blood specimen

Country Status (5)

Country Link
US (1) US20220146537A1 (zh)
EP (1) EP3919913A4 (zh)
JP (1) JP7402468B2 (zh)
CN (1) CN113366319A (zh)
WO (1) WO2020158948A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4116714A4 (en) * 2020-03-06 2024-01-10 Sekisui Medical Co Ltd METHOD FOR MEASURING BLOOD COAGULATION DURATION
US20240027476A1 (en) * 2020-09-08 2024-01-25 Sekisui Medical Co., Ltd. Blood coagulation reaction analysis method
WO2022092248A1 (ja) * 2020-10-29 2022-05-05 積水メディカル株式会社 血液凝固反応の検出方法
EP4303586A1 (en) * 2021-03-05 2024-01-10 Sekisui Medical Co., Ltd. Method for estimating factor of prolonged coagulation time
JP2022145224A (ja) 2021-03-19 2022-10-03 シスメックス株式会社 被検者の出血傾向を解析する解析方法、解析装置、解析システム、及び解析プログラム
WO2023032978A1 (ja) * 2021-08-31 2023-03-09 積水メディカル株式会社 血液凝固反応異常の検出方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524861B1 (en) * 1999-01-22 2003-02-25 Medical Laboratory Automation, Inc. Blood coagulation analyzer
US20060167369A1 (en) * 2004-12-22 2006-07-27 Montgomery Erwin B Jr Methods for identifying neuronal spikes
US20130344519A1 (en) * 2012-06-25 2013-12-26 Bayer Healthcare Llc Methods and systems for assessment of turbidity kinetics (waveform analysis) in coagulation testing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012173260A1 (ja) * 2011-06-17 2012-12-20 学校法人東日本学園・北海道医療大学 ループスアンチコアグラント検出用血液凝固時間の測定方法
US9739733B2 (en) * 2012-12-07 2017-08-22 T2 Biosystems, Inc. Methods for monitoring tight clot formation
JP6430809B2 (ja) 2014-12-19 2018-11-28 公立大学法人奈良県立医科大学 血液検体を判定するための方法、システム及びコンピュータプログラム、並びに血液検体分析装置
JP6871673B2 (ja) 2015-03-31 2021-05-12 学校法人東日本学園 血液検体を判定するための方法、装置及びコンピュータプログラム、並びに血液検体分析装置
CN107533071A (zh) * 2015-04-24 2018-01-02 公立大学法人奈良县立医科大学 血液受试体的凝固能力的评价方法、以及用于在该方法中使用的试剂、试剂盒及装置
JP6793916B2 (ja) * 2016-07-28 2020-12-02 公立大学法人奈良県立医科大学 血友病の重症度の判定方法及び血液検体分析装置
JP7002718B2 (ja) * 2017-04-24 2022-02-10 シスメックス株式会社 血液検体の分析方法、分析装置及びコンピュータプログラム
JP7220055B2 (ja) 2017-11-07 2023-02-09 積水メディカル株式会社 血液凝固機能の評価方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524861B1 (en) * 1999-01-22 2003-02-25 Medical Laboratory Automation, Inc. Blood coagulation analyzer
US20060167369A1 (en) * 2004-12-22 2006-07-27 Montgomery Erwin B Jr Methods for identifying neuronal spikes
US20130344519A1 (en) * 2012-06-25 2013-12-26 Bayer Healthcare Llc Methods and systems for assessment of turbidity kinetics (waveform analysis) in coagulation testing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Katayama, Haruna, et al. "An evaluation of hemostatic abnormalities in patients with hemophilia according to the activated partial thromboplastin time waveform." Clinical and Applied Thrombosis/Hemostasis 24.7 (2018): 1170-1176 (Year: 2018) *
Matsumoto, Takeshi, et al. "An evaluation of the activated partial thromboplastin time waveform." Clinical and Applied Thrombosis/Hemostasis 24.5 (2018): 764-770 (Year: 2018) *
Shapiro, Amy D, and Whitney Sealls. Hemophilia B. Wayback Machine, National Organization for Rare Disorders, web.archive.org/web/20170715000000*/https://rarediseases.org/rare-diseases/hemophilia-b/. Accessed 14 Mar. 2024 (Year: 2017) *

Also Published As

Publication number Publication date
CN113366319A (zh) 2021-09-07
EP3919913A4 (en) 2022-11-09
WO2020158948A1 (ja) 2020-08-06
JPWO2020158948A1 (ja) 2021-12-02
EP3919913A1 (en) 2021-12-08
JP7402468B2 (ja) 2023-12-21

Similar Documents

Publication Publication Date Title
US20220146537A1 (en) Method for analyzing blood coagulation characteristics of blood specimen
EP3882628A1 (en) Analysis method, analysis device, and analysis program
EP3988933A1 (en) Aptt prolongation factor estimation system
JP2019086517A (ja) 血液凝固機能の評価方法
JP2019086518A (ja) 血液凝固機能の評価方法
US20230393156A1 (en) Method for detecting blood coagulation reaction
US20220326262A1 (en) Method for measuring titer of coagulation factor inhibitor
US6787361B1 (en) Clinical assay calibration adjustment method
US20240027476A1 (en) Blood coagulation reaction analysis method
EP3136104B1 (en) Blood sample analyzing method and blood sample analyzer
US20230341371A1 (en) Blood analysis method
US20230341423A1 (en) Blood coagulation time measurement method
JP7491638B2 (ja) 血液分析方法
US20230213497A1 (en) Method for measuring blood coagulation time
US20240077504A1 (en) Method for estimating cause of prolonged coagulation time
Lippi et al. Biomarker validation in the emergency department. General criteria and clinical implications
US20230152335A1 (en) Blood coagulation time measurement method
Hölzel Analytical variation in immunoassays and its importance for medical decision making
Lewis Jr et al. Clinical significance of low-positive troponin I by AxSYM and ACS: 180
Bajo Comparison of the clauss and prothrombin time-derived fibrinogen methods in patients with dysfibrinogenemia, and Verification of their reference interval. Biom Case Rep Open A Open J. 2021; 2 (1): 44-57. doi: 10.33169/biomcase

Legal Events

Date Code Title Description
AS Assignment

Owner name: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHIMA, MIDORI;NOGAMI, KEIJI;OGIWARA, KENICHI;SIGNING DATES FROM 20210614 TO 20210705;REEL/FRAME:057026/0158

Owner name: SEKISUI MEDICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAWABE, TOSHIKI;ODA, YUKIO;SIGNING DATES FROM 20210608 TO 20210616;REEL/FRAME:057026/0070

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, JAPAN

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD ASSIGNOR'S EXECUTION DATE PREVIOUSLY RECORDED ON REEL 057026 FRAME 0158. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:SHIMA, MIDORI;NOGAMI, KEIJI;OGIWARA, KENICHI;SIGNING DATES FROM 20210615 TO 20210705;REEL/FRAME:059696/0130

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED